We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+33.72%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$783M
AUM Growth
+$288M
Cap. Flow
+$190M
Cap. Flow %
24.26%
Top 10 Hldgs %
60.08%
Holding
55
New
12
Increased
17
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$54M
2
ARRY
Array Biopharma Inc
ARRY
+$38.5M
3
TSRO
TESARO, Inc.
TSRO
+$29.3M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$21.5M
5
PCRX icon
Pacira BioSciences
PCRX
+$17.7M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$20.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$20.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$16.7M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 75.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASC
26
DELISTED
Cascadian Therapeutics, Inc.
CASC
$7.54M 0.96%
1,821,248
+900,000
+98% +$3.78M
CPRX
27
DELISTED
Catalyst Pharmaceutical
CPRX
$7.42M 0.95%
3,804,745
+2,663,596
+233% +$3.39M
BPMC
28
DELISTED
Blueprint Medicines
BPMC
$6.6M 0.84%
+165,000
New +$5.91M
SIOX
29
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.75M 0.73%
+48,073
New +$5.04M
VIVE
30
DELISTED
VIVEVE MED INC
VIVE
$5.63M 0.72%
+890
New +$4.33M
SRNE
31
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$4.71M 0.6%
1,192,130
-263,926
-18% -$1.32M
AKBA icon
32
Akebia Therapeutics
AKBA
$354M
$4.2M 0.54%
456,369
-375,146
-45% -$3.66M
FBIO icon
33
Fortress Biotech
FBIO
$104M
$3.69M 0.47%
66,444
-13,579
-17% -$607K
CRVS icon
34
Corvus Pharmaceuticals
CRVS
$1.12B
$2.53M 0.32%
121,715
-94,904
-44% -$1.49M
CLLS
35
Cellectis
CLLS
$277M
$2.33M 0.3%
97,096
– –
AVEO
36
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.32M 0.3%
+393,803
New +$2.84M
OTLK icon
37
Outlook Therapeutics
OTLK
$183M
$1.83M 0.23%
4,272
– –
BLCM
38
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.54M 0.2%
+12,500
New +$1.64M
TRIL
39
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.4M 0.18%
227,399
– –
ARRY
40
CALL
DELISTED
Array Biopharma Inc
ARRY
$390K 0.05%
+861,400
New +$9.17M
CLVS
41
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$258K 0.03%
+125,800
New +$7.65M
FOLD
42
CALL
DELISTED
Amicus Therapeutics
FOLD
$206K 0.03%
+250,000
New +$1.58M
ONSIW
43
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$187K 0.02%
233,333
– –
ONSIZ
44
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$117K 0.01%
233,333
– –
ACAD icon
45
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
– –
-200,000
Closed -$413K
AGEN
46
CALL
Agenus
AGEN
$312M
– –
-50,950
Closed -$25K
BMY icon
47
Bristol-Myers Squibb
BMY
$133B
– –
-285,000
Closed -$16.7M
NBIX icon
48
Neurocrine Biosciences
NBIX
$16.8B
– –
-541,000
Closed -$20.9M
SRPT icon
49
Sarepta Therapeutics
SRPT
$1.57B
– –
-1,010,300
Closed -$27.7M
SRPT icon
50
PUT
Sarepta Therapeutics
SRPT
$1.57B
– –
-150,000
Closed -$615K
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Avoro Capital Advisors held 55 positions worth $783M, up 58% from $495M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Avoro Capital Advisors deployed $190M of net new capital in Q1 2017, opening 12 new positions and adding to 17 existing holdings. Its largest new stake was Medicines Co: 1,185,000 shares worth $57.9M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier.

On the sell side, the largest reduction was NeuroDerm Ltd. Ordinary Shares, an estimated $11.6M trimmed.

  • Avoro Capital Advisors's largest Q1 2017 buy was Medicines Co: 1,185,000 shares worth $57.9M.
  • Avoro Capital Advisors added most to Array Biopharma Inc in Q1 2017, an estimated $38.5M increase.
  • Avoro Capital Advisors's biggest Q1 2017 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $11.6M.
  • Avoro Capital Advisors fully exited Sarepta Therapeutics in Q1 2017, selling an estimated $27.7M.
  • Avoro Capital Advisors's ten largest holdings make up 60% of its $783M portfolio in Q1 2017.
  • Avoro Capital Advisors opened 12 new positions and closed 10 in Q1 2017.
  • Avoro Capital Advisors's portfolio value rose 58% quarter-over-quarter to $783M.

Based on Avoro Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.